Exhibit 99.77b
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and Board of Trustees of
The Alger Funds:
In planning and performing our audit of the financial statements of The Alger Funds, comprised of Alger Capital Appreciation Fund, Alger Large Cap Growth Fund, Alger Mid Cap Growth Fund, Alger SMid Cap Growth Fund, Alger Small Cap Growth Fund, Alger Growth Opportunities Fund, Alger Health Sciences Fund, and Alger Growth & Income Fund (formerly Alger Balanced Fund) (the “Funds”), as of and for the year ended October 31, 2011, in accordance with the standards of the Public Company Accounting Oversight Board (United States), we considered the Funds’ internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N-SAR, but not for the purpose of expressing an opinion on the effectiveness of the Funds’ internal control over financial reporting. Accordingly, we express no such opinion.
The management of the Funds is responsible for establishing and maintaining effective internal control over financial reporting. In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls. A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and trustees of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of a company's assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.
A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Funds’ annual or interim financial statements will not be prevented or detected on a timely basis.
Our consideration of the Funds’ internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control that might be material weaknesses under standards established by the Public Company Accounting Oversight Board (United States). However, we noted no deficiencies in the Funds’ internal control over financial reporting and its operation, including controls for safeguarding securities, that we consider to be a material weakness, as defined above, as of October 31, 2011.
This report is intended solely for the information and use of management and the Board of Trustees of The Alger Funds and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties.
DELOITTE & TOUCHE LLP
New York, New York
December 23, 2011
Exhibit 99.77Q3
INDEPENDENT ACCOUNTANTS’ REPORT
To the Board of Trustees of The Alger Funds, The Alger Funds II, The Alger Institutional Funds, Alger China – U.S. Growth Fund, and The Alger Portfolios:
We have examined the procedures placed in operation by The Alger Funds, comprised of the Alger Capital Appreciation Fund, Alger Large Cap Growth Fund, Alger Mid Cap Growth Fund, Alger SMid Cap Growth Fund, Alger Small Cap Growth Fund, Alger Growth Opportunities Fund, Alger Health Sciences Fund, and Alger Growth & Income Fund; The Alger Funds II, comprised of the Alger Spectra Fund, Alger Analyst Fund, Alger Green Fund, Alger Dynamic Opportunities Fund, and Alger Emerging Markets Fund; The Alger Institutional Funds, comprised of the Alger Large Cap Growth Institutional Fund, Alger Mid Cap Growth Institutional Fund, Alger Small Cap Growth Institutional Fund, and Alger Capital Appreciation Institutional Fund; Alger China – U.S. Growth Fund; and The Alger Portfolios, comprised of the Alger Large Cap Portfolio, Alger Growth & Income Portfolio, Alger Mid Cap Growth Portfolio, Alger Small Cap Growth Portfolio, Alger SMid Cap Growth Portfolio, Alger Capital Appreciation Portfolio, and Alger Balanced Portfolio (collectively, the “Funds”) as of August 31, 2011, to achieve compliance with the terms and conditions of the application for (the “Application”) and order of exemption that was granted by the Securities and Exchange Commission dated August 11, 2009 permitting certain of the Funds to participate in a joint lending and borrowing facility (the “Interfund Lending Program”). Management is responsible for the Funds’ compliance with those requirements. Our responsibility is to express an opinion on the Funds’ compliance with the Application based on our examination.
Our examination was conducted in accordance with attestation standards established by the American Institute of Certified Public Accountants, and accordingly, included examining, on a test basis, evidence about the Funds’ compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.
We did not perform procedures to determine the operating effectiveness of controls for any period. Accordingly, we express no opinion on the operating effectiveness of any aspects of the Funds’ procedures to achieve compliance with the terms and conditions of the Application.
We believe that our examination provides a reasonable basis for our opinion. Our examination does not provide a legal determination on the Funds’ compliance with specified requirements.
Our examination disclosed the following instance of material noncompliance:
(i) Under Section II(D) of the Application, certain of the funds are barred by their fundamental policies from participating as lenders in the Interfund LendingProgram. The Alger Large Cap Growth Fund of The Alger Funds did not comply by participating as a lender in the Interfund Lending Program from May 9, 2011 to May 13, 2011.
In our opinion, except for the material noncompliance described in the preceding paragraph, The Alger Funds, The Alger Funds II, The Alger Institutional Funds, Alger China – U.S. Growth Fund, and The Alger Portfolios, as of August 31, 2011, complied with the terms and conditions of the Application and order of exemption that was granted by the Securities and Exchange Commission dated August 11, 2009.
This report is intended solely for the information and use of management and the Board of Trustees of the Funds, and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties.
Deloitte & Touche LLP
New York, New York
December 13, 2011